CHD4 and neoplasm: Moreover, our findings have important clinical consequences, since loss of CHD4 in primary and BRCA-deficient tumour cells confers resistance to treatment with poly ADP ribose polymerase (PARP) inhibitors and cisplatin.8 Thus, CHD4 represents a common mechanism that drives fork degradation in the absence of protective factors, perhaps by promoting fork reversal or by regulating local chromatin environments, and this in turn leads to chemo-sensitivity.